Web Watch

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Web Watch in One Page

The entire Onyx investment debate converges on one observable that does not print until November 2026: the H1FY27 operating margin. Below 7% confirms FY26's 1,200 bp margin collapse is structural; above 12% reframes it as Unit II ramp absorption. The other four watch items map directly to the report's highest-severity catalysts and failure modes — the FY26 Annual Report (the only scheduled venue where management has historically offered colour after filing FY26 results with no MD&A), the Unit I LVP first commercial shipment (the IPO equity story's missing proof point), Akums' cephalosporin / CDMO capex (Onyx's #1 ranked competitor is also a major customer with zero contractual protection), and any CDSCO or WHO-GMP regulatory event at the single-site Solan facility (where one Unit II audit failure removes the cephalosporin growth leg for 6-18 months). Together these five capture every signal the report names as capable of moving the 5-to-10-year thesis up or down a tier.

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	H1FY27 half-yearly result & operating-margin print	Daily	The single observable that resolves the entire bull/bear debate; every specialist tab names it as decisive. OPM above 12% reframes FY26 as ramp absorption and unlocks re-rating toward $0.57-0.62; at or below 7% confirms the no-moat reveal and opens the $0.17 downside path	Board-meeting pre-announcement and the H1FY27 standalone result filing (due by ~14 November 2026) — operating margin, half-yearly CFO, debtor days, short-term borrowings, any bad-debt provision against the $2.93M receivable book, and any management commentary or media interpretation against FY26 OPM 4.89% / H2FY26 7.02% / FY25 16.76%
2	FY26 Annual Report, AGM disclosures & governance signals	Daily	Management filed FY26 results with no MD&A, no concall, no forward statement after broken May-2025 "better FY26" guidance. The AR (due 30 Sep 2026) is the only scheduled venue to explain the margin collapse; FII holding has already collapsed 8.72% → 1.07% reading the silence	Annual Report filing, AGM notice and proceedings, MD&A content on cost lines that drove FY26, receivables ageing schedule, any bad-debt provision, related-party flows to Imperial India / S K Enterprises / Rosllion Healthcare, expanded unsecured promoter loans (currently $0.14M), auditor's report and any qualification on the $0.27M Note 38 Drawing Power reconciliation gap, and any change of statutory auditor
3	Unit I LVP commissioning & first commercial shipment	Daily	The highest-margin lever in the IPO use-of-proceeds; LVP carries 2-3x SWFI ampoule pricing. 18 months past the IPO timeline the machinery still shows "advance paid, bills awaited." Without LVP, the long-term thesis is stuck at commodity SWFI economics	Any NSE filing on LVP machinery installation, commissioning, validation batches, first commercial dispatch with a named anchor customer (Sun Pharma, Mankind, Aristo, Dr Reddy's, Macleods, Galpha), trade-press references, and the next statutory IPO utilisation auditor certificate (period ended 30 Sep 2026) including any redeployment-of-proceeds shareholder resolution
4	Akums cephalosporin / beta-lactam CDMO capex and partner-CDMO posture	Daily	Akums is Onyx's #1 ranked competitor AND a major loan-licensing customer with zero contractual protection (purchase-order basis only). Akums has publicly announced $37.3M of CDMO capex over two years that includes beta-lactam/cephalosporin segregation — internalising Onyx's only growth leg before Unit II fills is the report's #1 long-term failure mode	Akums quarterly result, concall transcripts, investor presentations, AR and filings mentioning in-house cephalosporin or beta-lactam DPI capex at Baddi, changes in Akums' partner-CDMO strategy, or commentary that quantifies third-party sterile injectable reliance
5	Solan single-site regulatory action (CDSCO, WHO-GMP, client audit)	Daily	Both units sit at one Solan location; one failed CDSCO inspection at Unit II's cephalosporin segregation suite halts the entire growth leg for 6-18 months. Next WHO-GMP renewal due ~May 2027; CDSCO surveillance and client audits are continuous. A product-line halt converts the existing working-capital squeeze ($0.43M cash, DSO 144, ST borrowings +84% YoY) into a going-concern event	CDSCO inspection observations, show-cause notices, licence suspensions, WHO-GMP renewal status changes, client audit findings disclosed by Sun / Mankind / Dr Reddy's / Aristo / Macleods / Akums / Hetero, batch recalls, Schedule M compliance actions, or HP State FDA actions against the Solan plots

Why These Five

The report's verdict is Watchlist for one reason: the entire debate hinges on a single number (H1FY27 OPM) that prints in November 2026, and four secondary watch items either feed into that number or test the assumptions surrounding it. Monitor #1 catches the H1FY27 number itself the day it lands. Monitor #2 catches the FY26 AR / AGM — the only governance venue where management has historically explained itself, and the test of whether the credibility deficit that drove FII holding from 8.72% to 1.07% in 18 months narrows or widens. Monitor #3 catches the LVP first-shipment disclosure that resolves the IPO use-of-proceeds credibility question and the highest-margin product-mix lever in the prospectus story. Monitor #4 catches Akums' competitor-customer asymmetry — the report's #1 long-term failure mode — through Akums' own quarterly disclosure cycle. Monitor #5 catches the single-site regulatory tail risk that would convert the working-capital squeeze into a going-concern event independent of the margin curve. Everything else in the report (the FII outflow, the promoter inactivity at sub-book, the tape-and-technical line at $0.33-$0.39) is implementation friction and credibility colour, not thesis content — and is observable from these five monitors as a downstream consequence rather than worth a dedicated watch.